ProfileGDS5678 / 1427949_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 86% 84% 84% 85% 82% 85% 85% 83% 84% 84% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.525186
GSM967853U87-EV human glioblastoma xenograft - Control 26.5610586
GSM967854U87-EV human glioblastoma xenograft - Control 36.5273486
GSM967855U87-EV human glioblastoma xenograft - Control 46.3842584
GSM967856U87-EV human glioblastoma xenograft - Control 56.218484
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1773585
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.800682
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3447785
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.331585
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1825883
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2312584
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2293984
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4151485
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1623584